Savara (SVRA) Gains from Investment Securities (2024)
Savara (SVRA) posted quarterly Gains from Investment Securities of $125000.0 for Q2 2024, up 495.24% quarter-over-quarter from $21000.0 in Q1 2024.
Powered by 
Analysis
Savara (SVRA) Gains from Investment Securities (2024) Analysis & Trends
Savara (SVRA) has reported Gains from Investment Securities for 4 consecutive years, with $125000.0 the latest figure, recorded in Q2 2024.
- In Q2 2024, Gains from Investment Securities changed N/A year-over-year to $125000.0; the TTM figure through Jun 2024 stood at $146000.0 (changed N/A YoY), while the FY2019 annual figure was $264000.0, down 0.75% from the prior year.
- Gains from Investment Securities advanced to $125000.0 in Q2 2024 per SVRA's latest filing, from $21000.0 in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $125000.0 in Q2 2024 and bottomed at $21000.0 in Q1 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Savara | 1.36 Bn | 1.36 Bn | - |